A carregar...
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
Anaplastic lymphoma kinase (ALK) inhibitors have demonstrated robust clinical activity in patients with ALK-rearranged lung cancers. The echinoderm microtubule-associated protein-like (EML)-ALK translocation was first discovered in 2007 and 4 years later, crizotinib, a first-generation ALK inhibitor...
Na minha lista:
| Publicado no: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7815371/ https://ncbi.nlm.nih.gov/pubmed/33489815 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-331 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|